Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
25 Setembro 2023 - 8:00AM
Business Wire
Studies have shown that using Castle’s
DecisionDx®-Melanoma test to help guide the care of patients with
melanoma, the deadliest form of skin cancer, improves health
outcomes1-5
Castle’s management team will also ring the New
York Stock Exchange closing bell on Sept. 28 as a member of the
Texas Capital Texas Equity Index exchange traded fund (ETF)
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that the Company will ring the Nasdaq closing bell on
Wednesday, Sept. 27, 2023, to raise awareness of melanoma in honor
of patients impacted by the disease.
“Castle is committed to our mission--improving health through
innovative tests that guide patient care,” said Derek Maetzold,
president and chief executive officer of Castle Biosciences and
IMPACT Melanoma board member. “We are grateful for the opportunity
to ring the closing bell in honor of patients with melanoma, their
families and caregivers, and importantly, their clinicians, who we
are privileged to partner with to help improve their care. At the
end of the day, we are all working together to make an impact in
people’s lives and perhaps provide something even more powerful
than that … hope for the future.”
Melanoma will claim nearly 20 American lives each day this year,
making it the most aggressive form of skin cancer.6 Castle’s
DecisionDx-Melanoma test is designed to provide personalized
information about a patient’s risk of melanoma recurrence,
metastasis and sentinel lymph node positivity based on the biology
of their tumor. This information can inform important decisions
regarding a patient’s treatment and follow-up care that have been
shown to improve health outcomes.1-5
Along with Castle’s leadership team at the Nasdaq closing bell
ceremony will be the following:
- Darrell Rigel, M.D., M.S., dermatologist, leading melanoma
expert and clinical professor of dermatology at the Mount Sinai
Icahn School of Medicine in New York. Rigel is also the co-creator
of the ABCDEs of early melanoma detection, a standard in today’s
dermatologic practice designed to help the public and clinicians
identify features of suspicious skin lesions.
- Ed Dobbles, D.B.A., IMPACT Melanoma board member. IMPACT
Melanoma is the nation’s leading non-profit dedicated to
significantly reducing the incidence of melanoma in the United
States and saving lives.
The live broadcast will begin at 3:50 p.m. Eastern Time from the
Nasdaq MarketSite Tower in New York. To view the broadcast, use
this link:
https://livestream.com/accounts/888332/events/10948952.
The following day, Thursday, Sept. 28, Maetzold and Frank
Stokes, chief financial officer, will join special guest Texas Gov.
Greg Abbott and other members of the Texas Capital Texas Equity
Index exchange traded fund (ETF) to ring the closing bell at the
New York Stock Exchange to celebrate the fund’s launch. The ETF is
comprised of 215 publicly listed companies headquartered in Texas
and is designed to reflect the performance of a diversified group
of companies having a material impact on the state’s economy.
About DecisionDx®-Melanoma
DecisionDx-Melanoma is a gene expression profile risk
stratification test. It is designed to inform two clinical
questions in the management of cutaneous melanoma: a patient’s
individual risk of sentinel lymph node (SLN) positivity and a
patient's personal risk of melanoma recurrence and/or metastasis.
By integrating tumor biology with clinical and pathologic factors
using a validated proprietary algorithm, DecisionDx-Melanoma is
designed to provide a comprehensive and clinically actionable
result to guide risk-aligned patient care. DecisionDx-Melanoma has
been shown to be associated with improved patient survival and has
been studied in more than 10,000 patient samples.
DecisionDx-Melanoma’s clinical value is supported by more than 40
peer-reviewed and published studies, providing confidence in
disease management plans that incorporate the test’s results.
Through June 30, 2023, DecisionDx-Melanoma has been ordered more
than 137,200 times for patients diagnosed with cutaneous melanoma.
More information about the test and disease can be found at
www.CastleTestInfo.com.
About IMPACT Melanoma
IMPACT Melanoma, a national non-profit 501(c)(3) organization,
is the nation’s leading non-profit dedicated to significantly
reducing the incidence of melanoma in the United States and saving
lives. The organization focuses on prevention education programs
that include customized and integrated programs for communities. In
addition to skin cancer prevention education and programs, IMPACT
Melanoma is committed to supporting melanoma patients and their
families and influencing urban development policies to address
shade equity in America. To learn more about IMPACT Melanoma, visit
https://impactmelanoma.org/.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
uveal melanoma, Barrett’s esophagus and mental health conditions.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to predict systemic therapy
response in patients with moderate-to-severe psoriasis, atopic
dermatitis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq,
TissueCypher and IDgenetix are trademarks of Castle Biosciences,
Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the “safe harbor” created by those
sections. These forward-looking statements include, but are not
limited to, statements concerning: the potential of
DecisionDx-Melanoma to inform important decisions regarding a
melanoma patient’s treatment and follow-up care and help guide
patient care and improve health outcomes. The words “can,” “may”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. We may not actually achieve the plans,
intentions or expectations disclosed in our forward-looking
statements, and you should not place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements that we make. These forward-looking
statements involve risks and uncertainties that could cause our
actual results to differ materially from those in the
forward-looking statements, including, without limitation:
subsequent study or trial results and findings may contradict
earlier study or trial results and findings, including with respect
to DecisionDx-Melanoma; actual application of our
DecisionDx-Melanoma test may not provide the aforementioned
benefits to patients; and the risks set forth under the heading
“Risk Factors” in our Annual Report on Form 10-K for the year ended
December 31, 2022, our Quarterly Report on Form 10-Q for the three
months ended June 30, 2023, and in our other filings with the SEC.
The forward-looking statements are applicable only as of the date
on which they are made, and we do not assume any obligation to
update any forward-looking statements, except as may be required by
law.
- Bailey CN, Martin BJ, Petkov VI, et al. 31-Gene Expression
Profile Testing in Cutaneous Melanoma and Survival Outcomes in a
Population-Based Analysis: A SEER Collaboration. JCO Precis. Oncol.
2023; 7. doi: 10.1200/PO.23.00044
- Dhillon S, Duarte-Bateman D, Fowler G, et al. Routine imaging
guided by a 31-gene expression profile assay results in earlier
detection of melanoma with decreased metastatic tumor burden
compared to patients without surveillance imaging studies. Arch
Dermatol Res. 2023.
https://doi.org/10.1007/s00403-023-02613-6.
- Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel
lymph node biopsy decisions in patients with T1-T2 melanoma using
gene expression profiling. Future Oncol. 2019;15(11):1207-1217.
doi: 10.2217/fon-2018-0912
- Whitman ED, Koshenkov VP, Gastman BR, et al. Integrating
31-gene expression profiling with clinicopathologic features to
optimize cutaneous melanoma sentinel lymph node metastasis
prediction. JCO Precis. Oncol. 2021; 5: 1466-1479. doi:
10.1200/PO.21.00162
- Yamamoto M, Sickle-Santanello B, Beard T, et al. The 31-gene
expression profile test informs sentinel lymph node biopsy
decisions in patients with cutaneous melanoma: results of a
prospective, multicenter study. Curr. Med. Res. Opin. 2023;39(3):
417-423. doi: 10.1080/03007995.2023.2165813
- American Academy of Dermatology;
https://www.aad.org/media/stats-skin-cancer; accessed Sept. 11,
2023
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230925508868/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024